What The Document Says

Increased GLP-1 receptor agonist signaling reduces the risk of paralytic ileus by directly improving gut motility

Best-supported causal claim extracted from weight loss drug glp-1.

Evidence Map

How the claim is supported

Prometheus organized 3,376 extracted causal statements from weight loss drug glp-1 into 191 evidence regions. The lists below show where support concentrates and which relation words dominate. Audit signals report cross-context consistency checks; they are not additional document claims.

Extracted claims3,376from 11 source records
Evidence regions191topic clusters supporting the claim map
Context warnings41190 translation checks
Agreement warnings4190 overlap checks

Evidence Regions

Topic clusters with the most supporting statements

Each row is a topic-like evidence region; the count is how many extracted statements landed there.

1telogen effluvium and androgenetic alopecia107claims
2improved drug accessibility and storage75claims
3tirzepatide dual glp 1 gip agonism65claims
4alopecia and hair loss events63claims
5altered glp 1 secretion and response45claims
6brain regions regulating drug reward44claims
7counseling on glp 1 receptor agonists43claims

Relation Mix

Relation words used across extracted claims

Each row counts a relation phrase, not a separate conclusion.

1leads to1,203uses
2reduces831uses
3increases546uses
4influences489uses
5affects176uses
6causes129uses
7contributes to2uses

Artifacts

Open the view you need